Cost-Effectiveness Inferences from Bootstrap Quadrant Confidence Levels: Three Degrees of Dominance

REFERENCES

• Black , W. C. ( 1990 ). The CE plane: A graphic representation of cost-effectiveness . Med. Decis. Making 10 : 212 – 214 .
   PubMed Web of Science ®Google Scholar
• Briggs , A. H. , Fenn , P. ( 1998 ). Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane (Student Corner) . Health Econ. 7 : 723 – 740 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Briggs , A. H. , Wonderling , D. E. , Mooney , C. Z. ( 1997 ). Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation . Health Econ. 6 : 327 – 340 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chaudhary , M. A. , Stearns , S. C. ( 1996 ). Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial . Stat. Med. 15 : 1447 – 1458 . [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cook , J. R. , Heyse , J. F. ( 2000 ). Use of an angular transformation for ratio estimation in cost-effectiveness analysis . Stat. Med. 19 : 2989 – 3003 . [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Copley-Merriman , C. , Egbuonu-Davis , L. , Kotsanos , J. G. , Conforti , P. , Franson , T. , Gordon , G. ( 1992 ). Clinical economics: A method for prospective health resource data collection . Pharmacoeconomics 1 ( 5 ): 370 – 376 .
   PubMedGoogle Scholar
• Goldstein , D. J. , Lu , Y. , Detke , M. J. , Wiltse , C. , Mallincrodt , C. , Demitrack , M. A. ( 2004 ). Duloxetine in the treatment of depression–-A double-blind, placebo-controlled comparison with paroxetine . J. Clin. Psychopharmacol. 24 : 389 – 399 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamilton , M. ( 1967 ). Development of a rating scale for primary depressive illness . British J. Soc. Clin. Psychol. 6 : 278 – 296 .
   PubMed Web of Science ®Google Scholar
• Laird , N. M. , Ware , J. H. ( 1982 ). Random-effects models for longitudinal data . Biometrics 38 : 963 – 974 .
   PubMed Web of Science ®Google Scholar
• Laska , E. M. , Meisner , M. , Siegel , C. , Stinnett , A. A. ( 1999 ). Ratio-based and net benefit-based approaches to health care resource allocation: Proofs of optimality and equivalence . Health Econ. 8 : 171 – 174 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lave , J. R. , Frank , R. G. , Schulberg , H. C. , Kamlet , M. S. ( 1998 ). Cost-effectiveness of treatments for major depression in primary care practice . Arch. Gen. Psychiatry 55 ( 7 ): 645 – 651 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mallinckrodt , C. H. , Clark , W. S. , David , S. R. ( 2001a ). Accounting for dropout bias using mixed-effects models . J. Biopharm. Stat. 11 : 1 – 13 . [CSA] [CROSSREF]
   PubMedGoogle Scholar
• Mallinckrodt , C. H. , Clark , W. S. , David , S. R. ( 2001b ). Type I error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via last observation carried forward . Drug Info. J. 35 : 1215 – 1225 .
   Web of Science ®Google Scholar
• O'Brien , B. J. , Drummond , M. F. , Labelle , R. J. , Willan , A. R. ( 1994 ). In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care . Med. Care 30 : 231 – 243 .
   Web of Science ®Google Scholar
• Obenchain , R. L. ( 1997 ). Issues and algorithms in cost-effectiveness inference . Biopharm. break Rep. 5 : 1 – 7 .
   Google Scholar
• Obenchain , R. L. ( 1999 ). Resampling and multiplicity in cost-effectiveness inference . J.~Biopharm. Stat. 9 ( 4 ): 563 – 582 . [CROSSREF]
   PubMedGoogle Scholar
• Obenchain , R. L. (2003). ICEplane: Microsoft Windows Software for Incremental Cost-Effectiveness Confidence Regions, Tolerance Regions, Acceptability and Net Benefit via Bootstrapping. Copyright © Pharmaceutical Research and Manufacturers of America (PhRMA). http://www.math.iupui.edu/~indyasa .
   Google Scholar
• Obenchain , R. L. , Melfi , C. A. , Croghan , T. W. , Buesching , D. P. ( 1997 ). Bootstrap analysis of cost-effectiveness in antidepressant pharmacotherapy . Pharmacoeconomics 11 ( 5 ): 464 – 472 . [CSA]
   PubMedGoogle Scholar
• Polsky , D. , Glick , H. , Willke , R. , Shulman , K. ( 1997 ). Confidence intervals for cost effectiveness ratios: A comparison of four methods . Health Econ. 6 : 243 – 252 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schoenbaum , M. , Unutzer , J. , Sherbourne , C. , Duan , N. , Rubenstein , L. V. , Miranda , J. , Meredith , L. S. , Carney , M. F. , Wells , K. ( 2001 ). Cost-effectiveness of practice-initiated quality improvement for depression: Results of a randomized controlled trial . JAMA 286 ( 11 ): 1325 – 1330 . [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stinnett , A. A. ( 1996 ). Adjusting for bias in C/E ratio estimates . Health Econ. 5 : 470 – 472 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stinnett , A. A. , Mullahy , J. ( 1998 ). Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis . Med. Decis. Making (Special Issue on Pharmacoeconomics) 18 : S68 – S80 . [CSA]
   PubMed Web of Science ®Google Scholar
• Tambour , M. , Zethraeus , N. ( 1998 ). Bootstrap confidence intervals for cost-effectiveness ratios: Some simulation results . Health Econ. 7 : 143 – 147 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Van Hout , B. A. , Al , M. J. , Gordon , G. S. , Rutten , F. F. ( 1994 ). Costs, effects and C/E ratios alongside a clinical trial . Health Econ. 3 : 309 – 319 . [CSA]
   PubMed Web of Science ®Google Scholar
• Willan , A. R. , O'Brien , B. J. ( 1999 ). Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data . Health Econ. 8 : 203 – 211 . [CSA] [CROSSREF]
   PubMed Web of Science ®Google Scholar